INTRODUCTION
TGF-β (transforming growth factor β) is a multifunctional cytokine that is involved in the regulation of various cellular responses including cell growth, differentiation, migration, apoptosis and ECM (extracellular matrix production). In particular, TGF-β1 is a key fibrogenic cytokine and disruption of TGF-β1 homoeostasis is linked to enhanced fibrogenesis [1] . The TGF-β signalling pathway is complex and often varies depending on the tissue type and other intracellular signalling pathways. TGF-β1 generates signals through a heteromeric complex of type I and type II TGF-β1 receptors [2] . The major pathway appears to involve Smad signalling. TGF-β binding to the type II receptor, initiates the signalling, and then recruits and activates type I receptor kinase which subsequently phosphorylates R-Smad2 (receptor-regulated Smad 2) and RSmad3 at their C-terminal SXSS motifs. The phosphorylated Smad2/3 associates with a common mediator, Smad4, and together they translocate into the nucleus where they regulate the transcription of TGF-β1 target genes [3] . Inhibitory Smads, such as Smad7, prevent Smad3 phosphorylation and thereby limit TGF-β1 signalling. The biological effects of TGF-β1 are also mediated through non-Smad-dependent signalling pathways including PI3K (phosphoinositide 3-kinase), Ras and JNK (cJun N-terminal kinase)/p38 [4] . Furthermore, there is sufficient evidence proving that TGF-β1 is involved in the RhoA activation which stimulates actin stress fibre formation [5] .
Many of the important effects of TGF-β1 on fibroproliferation and ECM production appear to be mediated by CTGF (connective tissue growth factor). CTGF is a cysteine-rich heparin-binding glycoprotein with a molecular mass of 38 kDa, and its expression level is dramatically increased in virtually all fibrotic conditions. CTGF expression has been reported to also be elevated in various cancers, such as glioma, melanoma, pancreatic cancer and HCC (human hepatocellular carcinoma) tissues [6] [7] [8] . HCC patients with high serum CTGF levels showed reduced survival, indicating an important role for CTGF in HCC progression [9, 8] . Because CTGF is a key downstream and co-operative mediator of TGF-β signalling, it is not surprising that the SMAD signalling pathway plays a critical role in the regulation of CTGF expression. Moreover, CTGF expression is also regulated by several other signalling pathways including PKC (protein kinase C), the small GTPase RhoA, JNK/p38 and PI3K [10, 11] . The final regulatory effects of CTGF are influenced by the interacting regulatory factors and cell type. Several of these pathways seem to act together and intensively cross-talk; however, specifically how these components interact to regulate CTGF expression has not yet been fully determined.
Several lines of evidence indicate that PKC is necessary to mediate the stimulatory effect of TGF-β in fibrogenesis [12] . PKC is a family of serine/threonine protein kinases that play a central role in various cellular activities. Depending upon their co-factor requirements, PKC members are classified into conventional (α, β and γ ), novel (δ, θ and ε) and atypical subfamilies [13] . PKC Abbreviations used: Cav-1, caveolin 1; CTGF, connective tissue growth factor; DMEM, Dulbecco's modified Eagle's medium; ECM, extracellular matrix; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GST, glutathione transferase; HCC, human hepatocellular carcinoma; JNK, c-Jun N-terminal kinase; PAI-1, plasminogen activator inhibitor-1; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PPM1A, protein phosphatase, Mg 2 + /Mn 2 + dependent, 1A; ROCK, Rho-associated kinase; R-Smad, receptor-regulated Smad; TBS-T, TBS with 0.1 % Tween 20; TGF-β, transforming growth factor β. 1 To whom correspondence should be addressed (email oskwon@knu.ac.kr).
also appears to play a critical role in tumour carcinogenesis. PKC isoforms were shown to display a variety of expression profiles during cancer progression depending on the specific type of cancer. PKCδ plays an important role in cellular functions, such as the control of growth, differentiation and apoptosis. Indeed, the role of PKCδ in inflammation and immunity has been confirmed using PKCδ-deficient mice [14] . Organ fibrosis may lead to organ failure and tumour development and is considered to be a major medical issue. Several studies have shown that PKCδ modulates the expression of collagen genes and up-regulation of PKCδ is involved in the pathogenesis of fibrotic disorders. These findings gave rise to hypothesis that PKCδ activation is closely connected to TGF-β1-mediated CTGF expression. However, the molecular circuitry that links PKCδ with TGF-β1-mediated CTGF expression and the subsequent regulation of tumour development and progression are poorly understood at this time. Therefore the major objective of the present study was to determine the role of PKCδ in HepG2 cells. The involvement of the PKCδ signalling pathway in the regulation of CTGF expression was explored in human hepatocarcinoma (HepG2) cells. On the basis of the results of the present study, we propose a regulatory mechanism of the PKCδ pathway induced by TGF-β1, and demonstrated that the PKCδ pathway plays a role in Smad2/3 phosphorylation and thus enhances CTGF production.
MATERIAL AND METHODS

Western blot analysis
Proteins from lysated cells were analysed by Western blotting. The membrane was exposed to specific polyclonal antibodies against CTGF (1:1000 dilution, Santa Cruz Biotechnology), phospho-PKCα (1:1000 dilution, Cell Signaling Technology), phospho-PKCδ (1:1000 dilution, Abcam), Smad3 (1:1000 dilution, Cell Signaling Technology), phospho-Smad2 (1:1000 dilution, Cell Signaling Technology), phosphoSmad3 (1:1000 dilution, Cell Signaling Technology), phosphop38 (1:1000 dilution, Cell Signaling Technology), phospho-JNK (1:1000 dilution, Cell Signaling Technology), LaminB1 (1:1000 dilution, Santa Cruz Biotechnology) and PPM1A (protein phosphatase, Mg 2 + /Mn 2 + dependent, 1A) (1:1000 dilution, Abcam). Non-specific antibody binding was blocked using 5 % BSA in TBS-T (TBS with 0.1 % Tween 20). The blots were incubated with a primary antibody in block solution for 2 h at room temperature (24 • C) and subsequently washed three times in TBS-T. The appropriate secondary antibody was added and then incubated for 1 h at room temperature. After washing three times with TBS-T, an ECL (enhanced chemiluminescence) detection system was applied for band visualization. The densities of the bands were quantified using the Quantity One 1D image analysis software program (Bio-Rad Laboratories). An anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) antibody (1:1000 dilution, Santa Cruz Biotechnology) was used as the loading control.
Cell culture
HepG2 cells (human hepatoma cells) were obtained from the A.T.C.C. (Manassas, VA, U.S.A). The HepG2 cells were grown in a humidified 5 % CO 2 atmosphere at 37
• C in DMEM (Dulbecco's modified Eagle's medium) culture including 10 % FBS, penicillin (100 units/ml) and streptomycin (50 μg/ml). These cultures were grown in six-well plates to 85 % confluence and then DMEM culture containing 0.1 % FBS, penicillin (100 units/ml) and streptomycin (50 μg/ml) was added for 12 h in order to arrest cell growth. The cells were then scraped off and lysed in 100 μl of RIPA buffer [1% Nonidet P40, 1 % sodium deoxycholate, 0.1 % SDS, 0.15 M NaCl, 0.01 M sodium phosphate (pH 7.2), 2 mM EDTA, 50 mM sodium fluoride and protease inhibitors] on ice and sonicated. Whole cell lysates were used for the Western blot analyses.
Immunofluorescence staining
Immunofluorescence staining was performed using an established procedure [15] . The cells were plated into two chamber slides with cover slips (Nalge Nuc International) with 0.5 ml of cell suspension added to each chamber. The next day, the cells had the appropriate medium added. On the day of staining, TGF-β1 (R&D Systems) was added to the appropriate chambers before staining of the cells. After the TGF-β1 incubation, the cells were washed with PBS, fixed in 4 % paraformaldehyde in PBS and then permeabilized in 0.05 % Triton X-100 in PBS for 10 min at room temperature. After permeabilization, the cells were washed for 1 min with 1× PBS three times at room temperature, followed by blocking with 10 % goat serum for 30 min. The serum was then removed and 500 μl of a 2% goat serum/1× PBS solution containing a 1:200 dilution of the primary antibody against Smad3 was added and then incubated at room temperature for 1 h. The cells were then washed five times for 1 min at room temperature in 1× PBS and then further incubated with 500 μl of a 2% goat serum/1× PBS solution containing a 1:400 dilution of a species-specific Alexa Fluor TM 488-labelled secondary antibody (Molecular Probes). Finally, the slides were washed three times in 1× PBS and mounted.
Transfection with siRNA
Duplex siRNA targeting PKCα, PKCδ, PPM1A and a control siRNA were purchased from Bioneer. For the siRNA experiments, the HepG2 cells were plated on 60-mm dishes at 70 % confluence. They were then transfected with PKCα, PKCδ, PPM1A and a control siRNA using the Lipofectamine TM 2000 reagent according to the manufacturer's instructions. The final concentration of PKCα, PKCδ, PPM1A and control siRNA in each well was 100 nM. After incubation for 6 h the cells were cultured in growth medium for 24 h and the expression levels of PKCα, PKCδ and PPM1A were determined by Western blot analysis.
RhoA pull-down assay
The pull-down assay was performed as described previously [16] . Briefly, the cells were lysed in hypertonic buffer and the GTP-bound RhoA was immunoprecipitated from the cleared lysate with 25 μg of glutathione-agarose-bound GST (glutathione transferase)-tagged rhotekin RhoA-binding domain (purified from the bacterial lysate). The beads were washed and the immunoprecipitate was resolved by SDS/PAGE (15 % gel). The membranes were probed with an anti-RhoA antibody. The lysate (50 μg) was also probed for RhoA in order to ensure equality was met across the conditions tested.
Statistical analysis
Analysis was performed using standard statistical software (SPSS for Windows, version 17.0). Results are presented as means + − S.E.M. and the comparison between groups was made using one-way ANOVA followed by the Student-NewmanKeuls test. P < 0.05 was considered statistically significant. Results shown as histograms are means + − S.D. for at least three (A) CTGF expression increased when the cells were exposed to TGF-β1, whereas treatment with SB431542 significantly attenuated its expression. In the left-hand panels, the dose dependency of CTGF expression following TGF-β1 stimulation was analysed by Western blotting. HepG2 cells were treated either without or with TGF-β1 (1 or 10 ng/ml) for 24 h. As shown in the right-hand panels, HepG2 cells were treated with TGF-β1 inhibitor SB431542 (1, 5 or 10 μM) for 1 h prior to incubation with TGF-β1 for 24 h. (B) To investigate the dependency of TGF-β1 in protein kinase activation, cells were incubated with TGF-β1 for 1 h. TGF-β1 significantly increased the levels of phospho-PKCα, phospho-PKCδ, phospho-p38 and phospho-JNK. (C) Specificity of protein kinases for CTGF expression. As shown in the upper panels, HepG2 cells were starved in serum-free DMEM for 24 h and then incubated with TGF-β1 and different types of protein kinase inhibitors: TGF-β1 type I receptor (SB431542, 10 μM), PKCα/PKCβ/PKCγ /PKCδ/PKCζ (Gö6983, 10 μM), PKCα/PKCβ1 (Gö6976, 0.5 μM) and PKCδ (Rottlerin, 1 μM). Cell lysates were prepared and CTGF expression with GAPDH was examined by Western blotting. Similarly, as shown in the lower panels p38 (SB203580, 10 μM) and PKCδ (Rottlerin, 1 μM) inhibitors were tested. Quantitative results of CTGF protein level were expressed graphically. The protein values have been normalized to GAPDH levels and then the expression levels were normalized against those in control cells. Results are means + − S.D. from duplicates in three independent experiments. independent experiments. The statistical significance level was represented at different values of P < 0.05.
RESULTS
PKCδ activity was required for TGF-β1-induced CTGF expression in HepG2 cells
The present study investigated how protein activation participates in TGF-β1-induced CTGF production using human hepatocyte HepG2 cells. Figure 1 (A) shows the dose-dependent increase in CTGF expression in response to TGF-β1. In contrast, pretreatment with SB431542, a TGF-β1 receptor inhibitor, was observed to dose-dependently down-regulate CTGF expression. PKC isoforms and other signalling proteins, such as p38 and JNK, were also shown to mediate TGF-β1 function. As shown in Figure 1 (B), several candidate proteins, such as PKCα, PKCδ, p38 and JNK, were clearly activated by treatment with 10 ng/ml of TGF-β1. In addition, we administered the specific inhibitors required to block individual signalling and then examined the expression of CTGF as induced by TGF-β1 ( Figure 1C ). Inhibition of TGF-β1 receptor kinase by SB431542 and general PKCs (i.e. α, β, γ , δ and ζ ) using 10 μM of Gö6983, a classic inhibitor of the Ca 2 + -dependent PKCα and β isoforms, blocked CTGF expression. More specifically, 0.5 μM Gö6976 showed no effect on the CTGF expression level, whereas a PKCδ inhibitor, Rottlerin (1 μM), dramatically reduced the TGF-β1-induced CTGF level. However, a p38 inhibitor (10 μM SB203580) also failed to block CTGF expression in HepG2 cells. Overall, these results indicated that, of the kinases tested in the present study, only PKCδ could be involved in TGF-β1-induced CTGF expression.
PKCδ has been implicated as an important modulator in the regulation of TGF-β1-dependent elastin and collagen expression [17] ; however, whether or not PKCδ activity is involved in the regulation of CTGF expression has remained unclear. Phosphorylation of Thr 505 in PKCδ is well known to produce enzyme activation [18] . Thus we confirmed that TGF-β1 stimulates PKCδ activity in a dose-dependent manner in HepG2 cells ( Figure 2A , upper left-hand panel). Interestingly, the level of phospho-PKCδ peaked at 30 min ( Figure 2A , lower lefthand panel). We found that treatment of the HepG2 cells with SB431542 for 1 h prior to the addition of 10 ng/ml TGF-β1 dramatically attenuated the phospho-PKCδ production ( Figure 2A , right-hand panels). These findings suggested that PKCδ is activated by TGF-β1, whereas inhibition of the TGF-β1 receptor resulted in blockage of PKCδ activation. To further confirm these results, HepG2 cells were transfected with either PKCα or PKCδ siRNAs and then evaluated by Western blotting. As shown in Figure 2 (B), knockdown of PKCδ resulted in a significant decrease in TGF-β1-stimulated CTGF production, whereas PKCα had no effect on this process. Additionally, treatment with Rottlerin significantly diminished TGF-β1's induction of CTGF in a dose-dependent manner in HepG2 and Hep3B cells ( Figure 2C and Supplementary Figure S1 at http://www.biochemj.org/bj/456/bj4560109add.htm).
Regulation of Smad2/3 signalling by PKCδ
The TGF-β1 receptor activates several enzymatic pathways including small GTPase, mitogen-activated protein kinases and PI3K [19] . These signalling pathways may cross-talk with Smad [20] . We examined previously how PKCδ participates in the Smad pathway [21, 22] . In order to elucidate the underlying signalling pathways, the levels of TGF-β1-induced Smad2/3 phosphorylation were determined in either the presence or absence of several inhibitors ( Figure 3A ). TGF-β1-induced Smad2/3 activation was specifically blocked by PKCδ inhibitor as well as TGF-β1 receptor inhibitor, whereas PKCα, JNK and p38 inhibitors showed no effect on this process. Similarly, knockdown of PKCδ by siRNA resulted in significant reduction in TGF-β1-induced phospho-Smad3 levels, but PKCα had no effect ( Figure 3B ). These results indicated that PKCδ activation may play a significant role in TGF-β1-induced Smad3 activation. It must be noted that we focused on Smad3 in this work as both Smad2 and Smad3 were activated by TGF-β1 to similar levels. The levels of the nuclear phospho-Smads reflect the strength of TGF-β1 signalling at any given time. As shown in Figure 3 (C) (left-hand panel), the levels of phospho-Smad3 increased within 10 min, peaked at 30 min and retained a plateau until at least 120 h, whereas pre-treatment with Rottlerin increased the levels whereas treatment with PKCα/PKCβ1 inhibitor (10 μM Gö6976) had no effect ( Figure 3C , middle panel).
There are accumulating data suggesting that, upon TGF-β1 stimulation, most Smad3 accumulates in the nucleus. The requirement for the participation of PKCδ, as well as TGF-β1, in the nuclear localization of phospho-Smad2/3 was determined by immunoblot analysis ( Figure 3D ). As expected, TGF-β1 rapidly stimulated not only PKCδ activation in the cytoplasm, but also C-terminal phosphorylation of Smad2/3, which resulted in the import of phospho-Smad2/3 into the nucleus. In the presence of a PKCδ inhibitor, the level of Smad3 phosphorylation and the nuclear translocation of phospho-Smad3 significantly dropped to their basal levels. Immunofluorescence analysis also confirmed TGF-β1-induced translocation of Smad3 into the nucleus of HepG2 cells ( Figure 3E ). In the absence of TGF-β1 treatment, Smad3 was found in the perinuclear region with a slight diffuse staining observed throughout the cell body. Upon stimulation with TGF-β1, the nuclear Smads, such as phospho-Smad, accumulated dramatically, whereas the signals in the perinuclear and cytoplasmic regions were totally depleted. Exposure of HepG2 cells to Rottlerin or SB431542 blocked TGF-β1-induced Smad3 translocation. Hence, PKCδ appeared to be involved in TGF-β1-induced Smad3 translocation. Interestingly, TGF-β1-induced Smad3 translocation was prevented by Rottlerin in a time-dependent manner. The level of nuclear Smad3 was not changed by the 30 min, but dramatically decreased thereafter (Supplementary Figure  S3 at http://www.biochemj.org/bj/456/bj4560109add.htm). Taken together, these results suggested that PKCδ activation is associated with the modulation of phospho-Smad levels and the nuclear translocation process.
PKCδ regulated RhoA/ROCK (Rho-associated kinase) activation
RhoA is known to be activated by TGF-β1 in several types of cells and its downstream effect, ROCK activation, is implicated in the up-regulation of CTGF [23] . Thus we assessed whether or not TGF-β1 can induce RhoA activation in HepG2 cells. As observed for phospho-PKCδ and phospho-Smad3, active GTPRhoA peaks at 30 min ( Figure 4A ). TGF-β1-induced RhoA activity was determined using a pull-down assay of GTP-bound RhoA. TGF-β1-induced RhoA activity was dose-dependent, but treatment with 1-10 μM SB431542 for 1 h attenuated GTP-RhoA activity ( Figure 4B ). Additionally, inactivation of PKCδ by Rottlerin blocked TGF-β1-induced RhoA activity in a dose-dependent manner, whereas Gö6976 had no effect. To further explore the putative role of PKCδ in TGF-β1-induced RhoA activity in HepG2 cells, the effect of siRNA-mediated knockdown regulation on RhoA activation was investigated. PKCδ siRNA, resulting in a 90 % knockdown in mRNA expression, caused a significant decrease in RhoA activation. On the other hand, down-regulation of PKCα affected the response much less ( Figure 4C ). Since the RhoA and Smad pathways are transmitted through TGF-β1 receptors, we examined whether or not blocking ROCK would prevent Smad3 activation. As expected, the ROCK inhibitor Y27632 attenuated TGF-β1-induced phosphorylation of Smad3 in a time-dependent manner ( Figure 4D ). Pre-treatment with Y27632 increased the levels of phospho-Smad3 by 30 min, but they significantly decreased thereafter. This result suggested that the level of phospho-Smad induced by TGF-β1 peaked at 30 min and PKCδ signalling plays a role in maintaining the levels after that. Y27632, a specific ROCK inhibitor, is known to prevent the up-regulation of CTGF [24] ; however, PKCδ and RhoA activity were not affected by Y27632, whereas the ROCK inhibitor decreased CTGF production in a dose-dependent manner ( Figure 4E) . In addition, we tested whether PKCδ and ROCK inhibitors could influence other classical TGF-β1 target genes such as PAI- We also explored the possibility that the activation of PKCδ is mediated through PPM1A, also known as Smad2/3 phosphatase. When the cells were treated with TGF-β1, the level of nuclear PPM1A remained elevated for 30 min, but gradually decreased thereafter ( Figure 5A ). In response to the presence of TGF-β1, PPM1A protein decreased and phospho-Smad3 was upregulated in the nucleus ( Figure 5B ). Conversely, Rottlerin pre-treatment rescued the basal level of PPM1A, but prevented the up-regulation of phospho-Smad3. In order to confirm the dependency of PPM1A in TGF-β1 signalling, we depleted the endogenous PPM1A using siRNA ( Figure 5C ). In the absence of inhibitors, the levels of phospho-Smad3 were further augmented in the PPM1A-knockdown transfectant as compared with those in the control transfectant. Interestingly, in an additional treatment with either SB431542 or Rottlerin, the control transfectants resulted in a dramatic reduction in phosphoSmad3 levels, whereas the PPM1A transfectants resulted in retained levels. The role of PPM1A was reflected by the level of accumulation of phospho-Smad3 in the nucleus. PPM1A plays an important role as a negative regulator of TGF-β1-induced Smad2/3 signalling. In agreement with the results described above, the levels of CTGF expression in the PPM1A transfectants were up-regulated as compared with the control. It must be noted that the suppression of PPM1A by the siRNA constructs stimulated CTGF expression even though TGF-β1 was absent. Overall, we demonstrated that PKCδ may negatively regulate PPM1A levels through the RhoA/ROCK pathway, thereby modulating the nuclear abundance of phospho-Smad3. The time course assessment data of PKCδ signalling was reanalysed. The TGF-β1-mediated phospho-Smad3 levels were retained for at least 120 min, whereas pre-treatment with TGF-β1 receptor inhibitor resulted in no induction of phospho-Smad3. However, as shown in Figures 3(C) and 4(D) , the TGF-β1-mediated phospho-Smad3 levels peaked at 30 min, and then dramatically decreased within a further 30 min in the presence of PKCδ or ROCK inhibitors. All of these changes in phosphoSmad3 level after 30 min are shown in Figure 6 (A). These results indicated that PKCδ may play a role in maintaining nuclear phospho-Smads at a maximal level. In conclusion, we propose (as shown in Figure 6B ) that TGF-β1 activates the Smad signalling and PKCδ pathways in parallel, but then these signals combine downstream at phospho-Smad2/3 in the nucleus. Thus CTGF protein levels are up-regulated by Smad signalling, whereas PKCδ, through PPM1A, regulates phospho-Smad production with significant synergy. PKCδ activation causes up-regulation of Rho/ROCK leading to the negative regulation of PPM1A, thereby sustaining the Smad2/3 level in the nucleus. The Smads dephosphorylated by PPM1A may be recycled back into the cytoplasm for the next round of signalling.
DISCUSSION
A key downstream and co-operative mediator of TGF-β signalling is CTGF. CTGF plays an important role in mediating many of the proliferative effects of TGF-β1, including the pathogenesis of tumour progression. Therefore it is of key importance to identify the pathways and mechanisms through which TGF-β1 regulates CTGF levels in fibrotic tissues. However, the precise regulatory mechanisms have not yet been fully determined. We have speculated that the main pathway through which TGF-β1 induces CTGF expression involves the Smad pathway, whereas certain gene targets of TGF-β appear to be regulated by a Smadindependent pathway. Thus our working model assumed that the PKCδ signalling pathway induced by TGF-β1 stimulation play a critical role in CTGF production in HepG2 cells. We demonstrated that PKCδ may regulate the Smad pathway indirectly, thereby playing an important role in TGF-β1-stimulated CTGF expression in HepG2 cells.
In the present study, we mainly focused our effort on determining the mechanism of the PKCδ signalling pathway in HepG2 cells. Our results pointed to several novel characteristics of PKCδ in HepG2 cells. First, we noted that the TGF-β1 signalling pathway was mediated, at least in part, by PKCδ activation. PKCδ signalling appeared to be responsible for CTGF expression. In the TGF-β1 signalling pathway, a potential regulatory mechanism by which PKCδ affects matricellular protein expression, such as observed in CTGF, has never been explored. Thus the results of the present study demonstrated for the first time that PKCδ activation is involved in CTGF expression in HepG2 cells, suggesting a novel role for PKCδ in stimulation. Secondly, although TGF-β1-induced PKCδ activation has been observed, the regulatory mechanism of the PKCδ signalling pathway has not been fully elucidated. We showed that PKCδ activation regulates nuclear PPM1A levels through the RhoA/ROCK pathway, providing important details about how the PKCδ pathway is linked to Smad signalling. Finally, an exciting finding from the present study was that blockage of the PKCδ pathway caused significant regression of the impact of the TGF-β1 signalling pathway. Our in vitro study showed that treatment using a PKCδ inhibitor or siRNA may prevent CTGF expression.
Numerous studies have implicated TGF-β1 and PKC as mediators of ECM accumulation [12, 18, 25] . In particular, the involvement of PKCδ in the TGF-β1-dependent regulation of ECM components has been proposed [17] . Previously, it has been shown that PKCδ is specifically activated by TGF-β1 in human mesangial cells and plays a role in collagen I accumulation via interaction with the Smad pathway [26] . Another study has demonstrated that TGF-β1-induced PKCδ activation regulates Smad3 activity resulting in transcriptional induction of COL1A2 (collagen, type I, α2) and fibronectin [27] . Moreover, PKCδ has been shown to be essential in TGF-β1-induced elastin synthesis in lung fibroblasts [28] . These results indicated that TGF-β1 could stimulate ECM accumulation in several cell types by modulating PKCδ activity. However, the role of the PKC isoforms in HCC tumorigenesis remains unclear. Thus we investigated the involvement of PKCδ in TGF-β1-stimulated CTGF expression using specific pharmacological inhibitors. The results of the present study clearly outlined, not only the predominant role that PKCδ plays in TGF-β1-mediated CTGF expression, but also that the exogenous administration of PKCδ inhibitor sufficiently blocked the TGF-β1 pathway. However, further studies are needed in order to clarify whether or not other novel-type PKC isoforms are involved in this regulation. Taken together, to the best of our knowledge, this was the first demonstration of the involvement of PKCδ in the regulation of CTGF expression in HepG2 cells and the impaired induction of PKCδ phosphorylation by TGF-β1.
Although the precise mechanism of how TGF-β modulates PKCδ activity remains unknown, we have demonstrated that TGF-β1-induced PKCδ can up-regulate CTGF expression. Thus we further speculated that PKCδ activation may participate in CTGF expression through modulation of the RhoA/ROCK pathway. In fact, the RhoA/ROCK pathway had already been implicated in TGF-β1 responses in various cell lines [29, 30] . RhoA activation was identified as involved in TGF-β1-induced CTGF production, and it was shown that ROCK inhibition leads to reduction of CTGF levels. In the present study, we showed that the presence of TGF-β1 significantly increased active RhoA in HepG2 cells and inactivation of PKCδ by Rottlerin decreased RhoA activity in a dose-dependent manner. Parallel experiments performed in HepG2 cells also demonstrated a significant reduction in RhoA GTP activity in response to PKCδ siRNA. These results suggested that the presence of PKCδ correlates with RhoA activity. Moreover, ROCK is a major downstream effector of RhoA GTPase signalling. ROCK inhibition significantly decreased CTGF expression and Smad2/3 phosphorylation in HepG2 cells. The present study demonstrated that RhoA/ROCK activation functions as a downstream target of PKCδ in the TGF-β1 signalling pathway. However, controversy may exist regarding the upstream target regulating RhoA signalling. For instance, a recent study has shown that TGF-β stimulates RhoA activation through Cav-1 (caveolin 1), with the result that RhoA signalling plays a critical role in TGF-β-induced PAI-1 production [31] . It is known that Cav-1 can be phosphorylated in order to facilitate interaction with other proteins. This discrepancy is most likely due to it being signalling-type-specific; however, the mechanism by which PKCδ modulates RhoA GTPase activity remains unclear. Previously, it was proposed that PKCδ may enhance RhoA activation and actin reorganization by regulating RhoA GTPase activity indirectly through upstream modulating proteins such as p190RhoGAP or p120RasGAP [32] .
TGF-β1-stimulated Rho/ROCK activation has been shown to regulate SMAD2/3 activity in order to induce liver disease, but the underlying molecular mechanism has not been well defined. Rho/ROCK signalling may modulate the duration of Smad2/3 phosphorylation and thus Smad-dependent transcriptional regulation of target genes [31] . Evidence suggests that PPM1A may also dephosphorylate Smad2/3 and block the TGF-β1 pathway [33] . Indeed, PPM1A is known to function as the phosphatase for the Smad2/3 responsible for the termination of TGF-β signalling. Involvement of PKCδ in Smad signalling was investigated in the present study and we showed that nuclear phospho-Smad2/3 levels were affected by PKCδ activity. In contrast, PKCδ blockage by Rottlerin did not directly interrupt either the C-terminal phosphorylation of Smad2/3 or its translocation into the nucleus ( Figure 3D ). It seems likely that the nuclear phospho-Smad2/3 level is indirectly modulated through PKCδ signalling in the cytosolic region. Hence, we hereby investigated whether or not TGF-β1-induced CTGF up-regulation is mediated by the PKCδ-PPM1A pathway. We demonstrated that RhoA/ROCK activation is a downstream target of PKCδ in the TGF-β1 signalling pathway. The blockage of the PKCδ pathway, prior to stimulation with TGF-β1, rescued the reduction in PPM1A levels. In contrast, PPM1A levels were reduced in response to TGF-β1 signalling, thereby resulting in the maintenance of nuclear phospho-Smad2/3 levels. These results are in agreement with a recent study showing that reduction in nuclear PPM1A phosphatase is positively regulated by the Rho/ ROCK pathway, accounting for the maintenance of the phosphoSmad2/3 levels required for gene induction [31] .
We demonstrated that, in the TGF-β1 signalling pathway, the level of nuclear phospho-Smad is indirectly regulated by PKCδ activation via PPM1A. The time course assessments indicated that, in human HepG2 cells, PKCδ inhibition by Rottlerin only marginally affected TGF-β1-stimulated Smad2/3 phosphorylation by 30 min, but it was completely blocked after that. The results reflected the TGF-β1-stimulated nuclear accumulation of Smad2/3 in the absence of PKCδ signalling ( Figure 3C ). In contrast, in the presence of PKCδ signalling, the level of phospho-Smads peaks at 30 min and remained at high levels until at least 120 h. This time-based control seemed to help in maintaining Smad3 levels in the nucleus. Therefore PKCδ signalling ultimately has an impact on not the initiation, but the maintenance of Smad3 phosphorylation after the peak time. The time course assessment of PKCδ signalling was further evaluated in the present study. PKCδ was activated by TGF-β1 in a timedependent manner with maximal activation at 30 min and GTPRhoA also peaked at 30 min ( Figure 4A) . Interestingly, the level of PPM1A had not changed by 30 min, but gradually decreased thereafter. The Smad2/3 phosphorylation resulting from TGF-β1 stimulation increased, whereas the dephosphorylation of nuclear Smad2/3 by PPM1A activity was blocked dramatically. Thus, consistent with the above observations, these processes may function to maintain maximal levels of phospho-Smads in the nucleus for extended periods.
In conclusion, we demonstrated for the first time that PKCδ activation is strongly stimulated by TGF-β1 in HepG2 cells and thus activated PKCδ is involved in the regulation of CTGF expression. In particular, TGF-β1 activated Smad signalling and the PKCδ pathway in parallel. TGF-β1 stimulated PKCδ activation resulting in a reduction in PPM1A via Rho/ROCK activation, thereby maintaining the phospho-Smad2/3 levels necessary for TGF-β1 gene induction. It should also be pointed out that PKCδ activation was shown to exhibit a positive correlation with the regulation of CTGF levels. 
